<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03492580</url>
  </required_header>
  <id_info>
    <org_study_id>CR108464</org_study_id>
    <secondary_id>RRA-20250</secondary_id>
    <nct_id>NCT03492580</nct_id>
  </id_info>
  <brief_title>A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease</brief_title>
  <official_title>Comparison of Canagliflozin vs. Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Patients With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of study is to estimate the incidence and comparative effect on health
      outcomes: 1) hospitalization for heart failure, 2) below knee lower extremity amputation. The
      date of first exposure to the particular drug(s) in the database, where the exposure start is
      between 1-April-2013 to 15-May-2017 and outcome data for these participants will be analyzed
      and reported in this study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Hospitalizations for Heart Failure</measure>
    <time_frame>Approximately 4-years</time_frame>
    <description>Number of hospital admissions with a primary diagnosis of 'heart failure' will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Below Knee Lower Extremity Amputation Events</measure>
    <time_frame>Approximately 4-years</time_frame>
    <description>Number of participants with new below-knee lower extremity amputation procedures, excluding recent (within 30 day) revisions will be reported.</description>
  </primary_outcome>
  <number_of_groups>12</number_of_groups>
  <enrollment type="Anticipated">714582</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Canagliflozin</arm_group_label>
    <description>A target cohort which includes new users of canagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. Truven Health MarketScan Commercial Claims and Encounters Database (CCAE) 2. Truven Health MarketScan Medicare Supplemental and Coordination of Benefits Database (MDCR) 3. Truven Health MarketScan Multi-state Medicaid Database (MDCD) 4. OptumInsight's de-identified Clinformatics Datamart, Extended-Date of Death (Optum).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Canagliflozin with Cardiovascular Disease (CVD)</arm_group_label>
    <description>A target cohort which includes new users of canagliflozin with established CVD for clinical characterization and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Empagliflozin</arm_group_label>
    <description>A comparator cohort which includes new users of empagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Empagliflozin with CVD</arm_group_label>
    <description>A comparator cohort which includes new users of empagliflozin with established CVD for clinical characterization and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: Dapagliflozin</arm_group_label>
    <description>A comparator cohort which includes new users of dapagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: Dapagliflozin with CVD</arm_group_label>
    <description>A comparator cohort which includes new users of dapagliflozin with established CVD for clinical characterization and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7: Empagliflozin or Dapagliflozin</arm_group_label>
    <description>A target cohort which includes new users of empagliflozin or dapagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8: Empagliflozin or Dapagliflozin with CVD</arm_group_label>
    <description>A target cohort which includes new users of empagliflozin or dapagliflozin with established CVD for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9: DPP-4 inhibitor (i)/ GLP-1 agonist (a)/ other AHA</arm_group_label>
    <description>A comparator cohort which includes new users of any dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) agonist, or other select antihyperglycemic agents (AHA) for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 10: DPP-4 (i)/ GLP-1 (a)/ other AHA with CVD</arm_group_label>
    <description>A comparator cohort which includes new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with established CVD for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 11: DPP-4 (i),GLP-1 (a),TZD, SU, insulin, other AHA</arm_group_label>
    <description>A comparator cohort which includes new users of any DPP-4 inhibitor, GLP-1 agonist, thiazolidinediones (TZD), sulfonylureas (SU), insulin, or other select AHA for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 12: DPP-4(i), GLP-1(a), TZD, SU, insulin, AHA with CVD</arm_group_label>
    <description>A comparator cohort which includes new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with established CVD for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canagliflozin</intervention_name>
    <description>No intervention or treatment assignment imposed by this study. Participants received canagliflozin as a part of routine clinical practice.</description>
    <arm_group_label>Cohort 1: Canagliflozin</arm_group_label>
    <arm_group_label>Cohort 2: Canagliflozin with Cardiovascular Disease (CVD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>No intervention or treatment assignment imposed by this study. Participants received empagliflozin as a part of routine clinical practice.</description>
    <arm_group_label>Cohort 3: Empagliflozin</arm_group_label>
    <arm_group_label>Cohort 4: Empagliflozin with CVD</arm_group_label>
    <arm_group_label>Cohort 7: Empagliflozin or Dapagliflozin</arm_group_label>
    <arm_group_label>Cohort 8: Empagliflozin or Dapagliflozin with CVD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>No intervention or treatment assignment imposed by this study. Participants received dapagliflozin as a part of routine clinical practice.</description>
    <arm_group_label>Cohort 5: Dapagliflozin</arm_group_label>
    <arm_group_label>Cohort 6: Dapagliflozin with CVD</arm_group_label>
    <arm_group_label>Cohort 7: Empagliflozin or Dapagliflozin</arm_group_label>
    <arm_group_label>Cohort 8: Empagliflozin or Dapagliflozin with CVD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dipeptidyl Peptidase-4 (DPP-4) Inhibitors</intervention_name>
    <description>No intervention or treatment assignment imposed by this study. Participants received DPP-4 inhibitor as a part of routine clinical practice. DPP-4 inhibitors includes: alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin.</description>
    <arm_group_label>Cohort 9: DPP-4 inhibitor (i)/ GLP-1 agonist (a)/ other AHA</arm_group_label>
    <arm_group_label>Cohort 10: DPP-4 (i)/ GLP-1 (a)/ other AHA with CVD</arm_group_label>
    <arm_group_label>Cohort 11: DPP-4 (i),GLP-1 (a),TZD, SU, insulin, other AHA</arm_group_label>
    <arm_group_label>Cohort 12: DPP-4(i), GLP-1(a), TZD, SU, insulin, AHA with CVD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon-like Peptide-1 (GLP-1) Agonist</intervention_name>
    <description>No intervention or treatment assignment imposed by this study. Participants received GLP-1 agonist as a part of routine clinical practice. GLP-1 agonists includes: albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide.</description>
    <arm_group_label>Cohort 9: DPP-4 inhibitor (i)/ GLP-1 agonist (a)/ other AHA</arm_group_label>
    <arm_group_label>Cohort 10: DPP-4 (i)/ GLP-1 (a)/ other AHA with CVD</arm_group_label>
    <arm_group_label>Cohort 11: DPP-4 (i),GLP-1 (a),TZD, SU, insulin, other AHA</arm_group_label>
    <arm_group_label>Cohort 12: DPP-4(i), GLP-1(a), TZD, SU, insulin, AHA with CVD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-hyperglycemic Agents (AHA)</intervention_name>
    <description>No intervention or treatment assignment imposed by this study. Participants received other selected AHA as a part of routine clinical practice. Other select AHAs includes: acarbose, bromocriptine, miglitol, nateglinide, repaglinide.</description>
    <arm_group_label>Cohort 9: DPP-4 inhibitor (i)/ GLP-1 agonist (a)/ other AHA</arm_group_label>
    <arm_group_label>Cohort 10: DPP-4 (i)/ GLP-1 (a)/ other AHA with CVD</arm_group_label>
    <arm_group_label>Cohort 11: DPP-4 (i),GLP-1 (a),TZD, SU, insulin, other AHA</arm_group_label>
    <arm_group_label>Cohort 12: DPP-4(i), GLP-1(a), TZD, SU, insulin, AHA with CVD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiazolidinediones (TZD)</intervention_name>
    <description>No intervention or treatment assignment imposed by this study. Participants received TZD as a part of routine clinical practice. TZDs includes: pioglitazone, rosiglitazone, troglitazone.</description>
    <arm_group_label>Cohort 11: DPP-4 (i),GLP-1 (a),TZD, SU, insulin, other AHA</arm_group_label>
    <arm_group_label>Cohort 12: DPP-4(i), GLP-1(a), TZD, SU, insulin, AHA with CVD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfonylureas (SU)</intervention_name>
    <description>No intervention or treatment assignment imposed by this study. Participants received SU as a part of routine clinical practice. SUs includes: glipizide, glyburide, glimepiride, chlorpropamide, tolazamide, tolbutamide, acetohexamide</description>
    <arm_group_label>Cohort 11: DPP-4 (i),GLP-1 (a),TZD, SU, insulin, other AHA</arm_group_label>
    <arm_group_label>Cohort 12: DPP-4(i), GLP-1(a), TZD, SU, insulin, AHA with CVD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>No intervention or treatment assignment imposed by this study. Participants received Insulin as a part of routine clinical practice.</description>
    <arm_group_label>Cohort 11: DPP-4 (i),GLP-1 (a),TZD, SU, insulin, other AHA</arm_group_label>
    <arm_group_label>Cohort 12: DPP-4(i), GLP-1(a), TZD, SU, insulin, AHA with CVD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants diagnosed with type 2 diabetes mellitus (T2DM) and established cardiovascular
        (CV) disease over a 4-year period 1 April 2013 and 15 May 2017 will be observed.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First exposure to the particular drug(s) in database (index date)

          -  Exposure start is between 1 April 2013 and 15 May 2017

          -  At least 365 days of continuous observation time prior to index

          -  At least 1 condition occurrence of 'Type II diabetes' any time in the prior continuous
             observation time (which is at least 365 days long) before or on the index date (first
             exposure to the particular drug(s) in database)

        For cohort with 'established cardiovascular disease - At least 1 occurrence of 'conditions
        indicating established cardiovascular disease' on or any time in the prior continuous
        observation time (which is at least 365 days long) prior to the index date

        Exclusion Criteria:

        - Participants with type 1 diabetes or secondary diabetes prior to or on the index date of
        exposure were excluded from the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Janssen Investigative Site</name>
      <address>
        <city>Titusville</city>
        <state>New Jersey</state>
        <zip>08560</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2018</study_first_submitted>
  <study_first_submitted_qc>April 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2018</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>2,4-thiazolidinedione</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Canagliflozin</mesh_term>
    <mesh_term>Hypoglycemic Agents</mesh_term>
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

